Market Analysis: Global Gonorrhea Treatment Market
Gonorrhea treatment market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Emergence of drugs used to treat risk associated with gonorrhea and high demand of disease specific novel therapies are the key factors that fueling the market growth.
Market Definition: Global Gonorrhea Treatment Market
Gonorrhea is also known as the clap is sexually transmitted disease caused by bacterium called Neisseria gonorrhoeae. It is transmitted by sexual fluids through oral, vaginal or anal sex. The infection affects the genitals, rectum, and the throat. Person with gonorrhea experienced pain or burning sensation when urinating, painful or swollen testicles, and increased vaginal discharge.
According to the Healthline Media UK Ltd, an estimated annual incidence of gonorrhea is approximately 78 million worldwide. In the United States alone have 820,000 new gonorrhea infections each year. Growing government support and rise in special designation from the regulatory authorities is driving the market growth
Get More Insights About Global Gonorrhea Treatment Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-gonorrhea-treatment-market
Market Drivers
• Rising prevalence of the gonorrhea worldwide is driving the growth of this market
• Huge financial support to the researchers for developing novel intervention is boosting the market growth
• High demand of disease specific novel treatment can also act as a market driver
• Increase in incidence of unprotected sex has led to an increase in the prevalence gonorrhea can propel the growth of this market
Market Restraints
• Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market
• Low healthcare budget in some developing countries is hamper the market growth
Segmentation: Global Gonorrhea Treatment Market
By Drug Class
• Sulfonamides
• Tetracycline
• Aminopenicillins
• Macrolides
By Drugs
• Erythromycin
• Clarithromycin
• Azithromycin
• Roxithromycin
• Others
By Route of Administration
• Oral
• Injectable
By End Users
• Hospitals
• Homecare
• Specialty Clinics
• Others
By Geography
• North America
o U.S.
o Canada
o Mexico
• South America
o Brazil
o Rest of South America
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Russia
o Turkey
o Belgium
o Netherlands
o Switzerland
o Rest of Europe
• Asia-Pacific
o Japan
o China
o South Korea
o India
o Australia
o Singapore
o Thailand
o Malaysia
o Indonesia
o Philippines
o Rest of Asia Pacific
• Middle East & Africa
o South Africa
o Rest of Middle East & Africa
Know more about this report https://www.databridgemarketresearch.com/reports/global-gonorrhea-treatment-market
Key Developments in the Market:
• In October 2017, Alopexx Vaccine LLC has completed the phase I clinical trial with AV0328, a vaccine targeting poly-N-acetyl glucosamine (PNAG) for the protection against many serious and life-threatening infections such as pneumonia, meningitis, bloodstream infections, and gonorrhea. In phase I clinical trial, AV0328 demonstrated excellent well-tolerated and safe which had no overall adverse event. If trial successful it will change treatment paradigms and improve the millions of people suffering from gonorrhea.
• In June 2017, MELINTA THERAPEUTICS, INC, reported positive result of RX-P2177, a novel pyrrolocytosine antibiotic is developing for the treatment of gonorrhea. The trial demonstrated the strong activity in vitro against contemporary clinical gonorrhea isolates, including those resistant to ceftriaxone, ciprofloxacin and azithromycin. This clinical trial results indicating potentially significant clinical benefits for patients with gonorrhea.
Competitive Analysis:
Global gonorrhea treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global gonorrhea treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Get Access Report @ https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-gonorrhea-treatment-market
Key Market Players:
Few of the major competitors currently working in the global gonorrhea treatment market are GlaxoSmithKline plc, MELINTA THERAPEUTICS, INC, Alopexx Vaccine LLC, AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Ltd, LUPIN, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Mylan N.V., Hikma Pharmaceuticals PLC, WOCKHARDT, Nostrum Laboratories Inc, Mayne Pharma Group Limited, Apotex Inc, Pfizer Inc, Genocea Biosciences, Inc and others
Primary Respondents
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Request for Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-gonorrhea-treatment-market
Browse Trending Related Reports @
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
• Dementia Treatment Market
• Erythromelalgia Treatment Market
• Centronuclear Myopathies Drug Market
• Heatstroke Treatment Market
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]